Annual report pursuant to Section 13 and 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.23.1
Significant Strategic Collaborations (Details Narrative) - USD ($)
 12 Months Ended
Oct. 12, 2021
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue   $ 1,706,925 $ 1,160,692
Research and development expenses   4,770,834 3,163,485
Prepaid Expense and Other Assets, Current   556,094 479,399
Revenues   1,706,925 1,160,692
Co Development Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues   $ 0 $ 0
Pharmsynthez [Member] | Series B Preferred Stock [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Warrants outstanding   1,500,000  
Pharmsynthez [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Percent ownership in Xenetic   2.90% 3.30%
Takeda [Member] | Royalty Revenue [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue   $ 1,700,000 $ 1,200,000
Catalent Pharma Solutions [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development expenses   700,000  
Prepaid Expense and Other Assets, Current   300,000  
Scripps Research [Member] | Scripps Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development expenses   2,400,000  
Prepaid Expense and Other Assets, Current   0 200,000
Pharmsynthez [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
[custom:MilestonePaymentsMade]   100,000  
Payments for Other Fees $ 40,000    
Pharmsynthez [Member] | Master Services Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development expenses   $ 0 $ 100,000